Literature DB >> 25982652

Symplicity multi-electrode radiofrequency renal denervation system feasibility study.

Robert Whitbourn1, Scott A Harding, Antony Walton.   

Abstract

AIMS: The aim of this study was to test the safety and performance of the Symplicity™ multi-electrode radio-frequency renal denervation system which was designed to reduce procedure time during renal denervation. METHODS AND
RESULTS: The multi-electrode radiofrequency renal denervation system feasibility study is a prospective, non-randomised, open label, feasibility study that enrolled 50 subjects with hypertension. The study utilises a new renal denervation catheter which contains an array of four electrodes mounted in a helical configuration at 90 degrees from each other to deliver radiofrequency energy simultaneously to all four renal artery quadrants for 60 seconds. The protocol specified one renal denervation treatment towards the distal end of each main renal artery with radiofrequency energy delivered for 60 seconds per treatment. Total treatment time for both renal arteries was two minutes. The 12-month change in office systolic blood pressure (SBP) and 24-hour SBP was -19.2±25.2 mmHg, p<0.001, and -7.6±20.0 mmHg, p=0.020, respectively. There were three patients with access-site complications, none of which was related to energy delivery; all were treated successfully. No new renal artery stenosis or hypertensive emergencies occurred.
CONCLUSIONS: The Symplicity multi-electrode radiofrequency renal denervation system was associated with a significant reduction in SBP at 12 months and minimal complications whilst it also reduced procedure time. TRIAL REGISTRATION: NCT01699529.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25982652     DOI: 10.4244/EIJV11I1A18

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  4 in total

1.  Procedural Reassessment of Radiofrequency Renal Denervation in Resistant Hypertensive Patients.

Authors:  Franco Rabbia; Elisa Testa; Chiara Fulcheri; Elena Berra; Silvia Di Monaco; Michele Covella; Marco Pappaccogli; Silvia Monticone; Renato Rosiello; Denis Rossato; Franco Veglio
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-03

Review 2.  Renal denervation in resistant hypertension: a review of clinical trials and future perspectives.

Authors:  Eiichiro Yamamoto; Daisuke Sueta; Kenichi Tsujita
Journal:  Cardiovasc Interv Ther       Date:  2022-04-26

Review 3.  Device-based therapies for arterial hypertension.

Authors:  Lucas Lauder; Michel Azizi; Ajay J Kirtane; Michael Böhm; Felix Mahfoud
Journal:  Nat Rev Cardiol       Date:  2020-04-14       Impact factor: 32.419

4.  Effect of renal denervation on catecholamines and the renin-angiotensin-aldosterone system.

Authors:  Lida Feyz; Sjoerd van den Berg; Robert Zietse; Isabella Kardys; Jorie Versmissen; Joost Daemen
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Jul-Sep       Impact factor: 1.636

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.